Consensus ADC Therapeutics SA

Stocks

ADCT

CH0499880968

Biotechnology & Medical Research

Market Closed - NYSE 23:00:02 18/08/2026 +03			5-day change	1st Jan Change
1.030 ^USD	-6.36%		-12.71%	-70.82%

08-14	ADC Therapeutics Balances LOTIS-5 Regulatory Risk With LOTIS-7 Opportunity, RBC Says	MT
08-13	ADC Therapeutics SA, Q2 2026 Earnings Call, Aug 13, 2026

Evolution of the Average Target: ADC Therapeutics SA

Evolution of the Target Price: ADC Therapeutics SA

Changes in Analyst Recommendations: ADC Therapeutics SA

539041076146d896615cfe9.No0USdBqdmfAbyGbuV9joGOoZJ4eg9W3J0bVe_KkYt4.VcVmMaAlBVOEV1nZyig5xFTdDftH-ZzOQnenOrvnU-kD3XV_lSkgAZcaQg~0b092b4f182ffba246d3ece6cfe1bfae

Analysts' recommendations: ADC Therapeutics SA

08-14	ADC Therapeutics Balances LOTIS-5 Regulatory Risk With LOTIS-7 Opportunity, RBC Says	MT
06-08	ADC Therapeutics Shares Fall After HC Wainwright Downgrade	MT
06-08	HC Wainwright Downgrades ADC Therapeutics to Neutral From Buy	MT
06-04	Top Midday Decliners	MT
06-04	RBC Downgrades ADC Therapeutics to Sector Perform From Outperform, Cuts Price Target to $2 From $6, Keeps Speculative Risk	MT
20/06/25	RBC Adjusts Price Target on ADC Therapeutics Ltd to $5 From $8, Maintains Outperform, Speculative Risk Rating	MT
08/11/24	Stephens Starts ADC Therapeutics With Overweight Rating, $6 Price Target	MT
30/05/24	Cantor Fitzgerald Initiates ADC Therapeutics at Overweight Rating	MT
07/05/24	HC Wainwright Adjusts Price Target on ADC Therapeutics to $8 From $9, Maintains Buy Rating	MT
28/03/24	Guggenheim Initiates ADC Therapeutics With Buy Rating, $11 Price Target	MT
26/02/24	RBC Lifts Price Target on ADC Therapeutics to $8 From $6, 'Encouraged' by Competitive Positioning; Outperform, Speculative Risk Kept	MT
20/02/24	HC Wainwright Raises Price Target on ADC Therapeutics to $9 From $3, Maintains Buy Rating	MT
20/11/23	HC Wainwright Adjusts Price Target on ADC Therapeutics to $3 From $12, Keeps Buy Rating	MT
09/11/23	TD Cowen Downgrades ADC Therapeutics to Market Perform From Outperform	MT
08/11/23	RBC Cuts Price Target on ADC Therapeutics to $6 From $7, Keeps Outperform, Speculative Risk	MT
12/09/23	RBC Trims Price Target on ADC Therapeutics to $8 From $9 Amid Guidance Withdrawal, Keeps Outperform, Speculative Risk	MT
10/08/23	JPMorgan Upgrades ADC Therapeutics to Neutral From Underweight	MT
09/08/23	RBC Trims Price Target on ADC Therapeutics to $9 From $10, Maintains Outperform Rating, Speculative Risk Qualifier	MT
20/06/23	HC Wainwright Lowers Price Target on ADC Therapeutics to $12 From $20, Maintains Buy Rating	MT
10/05/23	RBC Cuts Price Target on ADC Therapeutics to $10 From $12, Maintains Outperform Rating, Speculative Risk Qualifier	MT
24/04/23	BofA Securities Downgrades ADC Therapeutics to Underperform From Neutral, Adjusts Price Target to $2 From $7	MT
13/02/23	RBC Cuts Price Target on ADC Therapeutics to $12 From $18, Maintains Outperform, Speculative Risk	MT
24/01/23	Morgan Stanley Lowers Price Target on ADC Therapeutics to $5 From $7, Maintains Equalweight Rating	MT
04/01/23	HC Wainwright Adjusts Price Target on ADC Therapeutics SA to $20 From $21, Maintains Buy Rating	MT
14/11/22	Morgan Stanley Adjusts Price Target on ADC Therapeutics SA to $7 From $11, Maintains Equal-Weight Rating	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	ADC THERAPEUTICS SA					+203.03%
	WUXI APPTEC CO., LTD.					+9.37%
	ARGENX SE					+4.68%
	INSMED INCORPORATED					+55.9%
	WUXI BIOLOGICS (CAYMAN) INC.					+2.95%
	BIONTECH SE					+31.58%
	GENMAB A/S					+14.57%
	PHARMAESSENTIA CORPORATION					-6.94%
	SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.					+9.69%
	EXELIXIS, INC.					+1.18%
	Average					+32.60%
	Weighted average by Cap.					+13.33%